acut
respiratori
distress
syndrom
ard
character
diffus
lung
injuri
sever
hypoxemia
high
rate
fatal
even
roughli
develop
variou
pathogen
condit
lung
injuri
trigger
inhal
airborn
caus
agent
design
direct
lung
injuri
develop
context
system
disord
sepsi
design
indirect
lung
injuri
direct
lung
injuri
report
occur
infect
sever
acut
respiratori
syndrom
sar
viru
highli
pathogen
avian
influenza
viru
serum
level
interferon
ifn
tumor
necrosi
factor
tnf
elev
case
fatal
human
influenza
viru
infect
sever
cytokin
includ
show
strikingli
increas
concentr
bronchoalveolar
lavag
bal
fluid
patient
anim
model
direct
lung
injuri
induc
intratrach
administr
lipopolysaccharid
lp
acut
robust
influx
inflammatori
cell
lung
observ
inflammatori
chang
complet
resolv
within
h
without
demonstr
either
alveolar
epitheli
injuri
vascular
leakag
typic
histopatholog
featur
ard
recent
report
anim
model
fulmin
ard
establish
sensit
mice
potent
activ
natur
killer
nkt
cell
follow
challeng
lp
model
mice
rapidli
die
diffus
alveolar
damag
lung
accompani
strike
increas
concentr
bal
fluid
varieti
proinflammatori
cytokin
chemokin
report
play
critic
role
pathogen
mechan
ard
wherea
lower
product
antiinflammatori
mediat
receptor
antagonist
associ
gener
poor
prognosi
base
understand
involv
cytokin
variou
antiinflammatori
agent
includ
corticosteroid
statin
prostaglandin
neutrophil
elastas
inhibitor
inhibitor
arachidon
acid
metabol
test
clinic
efficaci
ard
therapi
howev
truli
efficaci
agent
yet
establish
type
ifn
discov
endogen
synthes
antivir
protein
deepli
involv
acut
chronic
inflammatori
respons
includ
delayedtyp
hypersensit
experiment
autoimmun
encephalomyel
collageninduc
arthriti
addit
nonantivir
action
cytokin
inhibit
divis
certain
tumor
cell
line
promot
cytolyt
activ
nk
cell
cell
enhanc
express
mhc
molecul
thu
type
ifn
gradual
recogn
import
player
cytokin
network
lead
regul
innat
acquir
immun
respons
clinic
set
type
ifn
use
treatment
viral
hepat
multipl
sclerosi
recent
anim
experi
antiinflammatori
effect
result
type
ifn
administr
report
experiment
autoimmun
encephalomyel
rheumatoid
arthriti
bacteri
periton
lung
inflamm
background
mind
present
studi
address
type
ifn
affect
clinic
cours
inflammatori
respons
mous
model
fulmin
ard
sensit
challeng
lp
found
lowdos
administr
improv
surviv
attenu
inflammatori
respons
fulmin
ard
mice
effect
associ
suppress
synthesi
lung
mice
bred
pathogenfre
environ
institut
anim
experiment
tohoku
univers
graduat
school
medicin
mice
use
experi
week
age
experiment
protocol
describ
present
studi
approv
ethic
review
committe
anim
experiment
tohoku
univers
purchas
funakoshi
tokyo
japan
dissolv
dimethyl
sulfoxid
dmso
sigmaaldrich
st
loui
mo
usa
mgml
dilut
phosphatebuff
salin
pb
final
dose
dmso
vivo
use
lp
escherichia
coli
purchas
sigmaaldrich
induc
lung
injuri
mice
anesthet
intraperiton
inject
mgkg
pentobarbit
abbott
laboratori
north
chicago
il
usa
restrain
small
board
inject
mous
insert
intraven
cathet
terumo
tokyo
japan
trachea
twentyfour
hour
later
lp
administ
via
rout
shamoper
mice
inject
dmsocontain
pb
dpb
trachea
h
later
pb
administ
via
rout
recombin
human
provid
nippon
roch
research
center
kamakura
japan
mice
administ
variou
amount
intranas
variou
time
interv
lp
inject
administr
intratrach
lp
time
h
lung
mice
treat
pb
weigh
h
lp
challeng
determin
final
wet
lung
weight
dri
oven
h
weigh
determin
dri
weight
wetdri
wd
weight
ratio
calcul
lung
specimen
obtain
mice
fix
buffer
formalin
dehydr
embed
paraffin
section
cut
stain
stain
use
standard
stain
procedur
biomed
research
core
anim
patholog
platform
tohoku
univers
graduat
school
medicin
measur
histolog
evid
tissu
injuri
use
lung
injuri
score
system
recommend
american
thorac
societi
at
lung
injuri
score
system
paramet
includ
neutrophil
alveolar
space
neutrophil
interstiti
space
hyalin
membran
proteinac
debri
fill
airspac
alveolar
septal
thicken
least
random
highpow
field
total
magnif
independ
score
blind
fashion
five
histolog
find
grade
use
threetier
scheme
summar
tabl
sum
five
independ
variabl
shown
tabl
weight
accord
relev
ascrib
featur
at
committe
normal
number
field
evalu
mice
sacrif
h
lp
exposur
chest
open
trachea
cannul
g
iv
cathet
ml
pb
infus
intratrach
withdrawn
procedur
perform
three
time
bal
fluid
store
cytokin
measur
collect
bal
fluid
pulmonari
circul
rins
inject
ml
pb
right
ventricl
lung
harvest
store
ml
pb
lung
pb
later
homogen
centrifug
rpm
min
supernat
store
cytokin
measur
concentr
supernat
lung
homogen
bal
fluid
measur
elisa
use
captur
biotinyl
develop
antibodi
bd
bioscienc
franklin
lake
nj
usa
detect
limit
pgml
respect
analysi
data
conduct
use
jmp
softwar
sa
institut
inc
cari
nc
usa
macintosh
comput
data
express
mean
sd
statist
analysi
group
perform
use
analysi
varianc
post
hoc
analysi
fisher
protect
least
signific
differ
test
surviv
data
analyz
use
logrank
test
p
valu
consid
signific
earlier
studi
intratrach
administr
lp
follow
sensit
led
develop
fulmin
ard
mice
caus
fatal
outcom
within
h
lp
inject
current
studi
investig
whether
affect
clinic
cours
fulmin
ard
mice
purpos
mice
treat
variou
dose
iu
iu
iumous
pb
vehicl
control
h
simultan
h
h
h
lp
inject
shown
fig
mice
treat
pb
die
within
h
wherea
treatment
lowdos
iumous
significantli
prolong
surviv
durat
fulmin
ard
mice
howev
higher
dose
iu
iumous
prolong
surviv
result
demonstr
lowdos
highdos
protect
mice
death
caus
fulmin
ard
next
address
effect
administr
lung
injuri
develop
fulmin
ard
mice
conduct
histopatholog
analys
use
result
illustr
fig
basi
lpschalleng
mice
treat
lowdos
iumous
pb
lung
section
stain
analyz
microscop
h
lp
challeng
shown
fig
massiv
infiltr
neutrophil
intraalveolar
septa
also
alveolar
space
observ
lpschalleng
mice
receiv
pb
treatment
wherea
inflammatori
respons
strikingli
attenu
mice
treat
lowdos
object
evalu
inflammatori
chang
quantifi
histolog
chang
tissu
injuri
use
lung
injuri
score
system
shown
fig
lung
injuri
score
significantli
lower
lowdos
mice
control
mice
result
indic
lowdos
effect
inhibit
develop
fard
caus
sensit
lp
challeng
addit
evalu
degre
lung
edema
characterist
ard
examin
wd
lung
weight
ratio
h
lp
challeng
fig
show
wd
lung
weight
ratio
significantli
lower
mice
treat
pbstreat
mice
level
former
mice
almost
equival
shamoper
mice
result
clearli
demonstr
lowdos
treatment
mitig
develop
fulmin
ard
attenu
inflammatori
respons
lung
investig
mechan
benefici
effect
fulmin
ard
evalu
synthesi
lung
report
critic
cytokin
mous
model
fulmin
ard
purpos
concentr
cytokin
bal
fluid
lung
homogen
measur
h
lp
challeng
shown
fig
treatment
lowdos
significantli
reduc
level
bal
fluid
lung
homogen
lpschalleng
mice
compar
pbstreat
mice
level
lung
homogen
mice
almost
low
shamoper
mice
synthesi
lung
determin
assay
bal
fluid
lung
homogen
also
augment
mice
sensit
challeng
lp
strike
contrast
observ
impact
upon
level
lowdos
treatment
reduc
synthesi
lung
measur
assay
two
type
lung
specimen
fig
present
studi
demonstr
administr
lowdos
prolong
surviv
fulmin
ard
mice
sensit
challeng
lp
high
dose
provid
benefit
lowdos
treatment
attenu
diffus
alveolar
damag
occur
consequ
massiv
infiltr
neutrophil
typic
histolog
featur
ard
reduc
wd
lung
weight
ratio
indic
lung
edema
compar
pbstreat
group
lowdos
treatment
led
decreas
product
accord
assay
bal
fluid
lung
homogen
fulmin
ard
mice
result
indic
lowdos
antiinflammatori
therapeut
effect
mous
model
fulmin
ard
suggest
reduc
product
lung
may
involv
benefici
effect
treatment
infect
highli
pathogen
avian
influenza
viru
report
caus
fulmin
ard
histopatholog
defin
diffus
alveolar
damag
lung
often
refractori
even
advanc
medic
therapi
pathogen
condit
associ
viral
replic
bronchial
epitheli
cell
also
uncontrol
product
inflammatori
cytokin
socal
cytokin
storm
lung
associ
fatal
outcom
mani
case
thu
control
excess
inflammatori
respons
may
provid
effect
therapeut
target
fulmin
ard
caus
influenza
viru
type
ifn
synthes
secret
virusinfect
cell
upregul
express
antivir
gene
render
host
resist
infect
recent
haasbach
et
al
demonstr
lowdos
type
ifn
treatment
effect
protect
mice
infect
influenza
viru
though
effect
thought
due
antivir
activ
type
ifn
remain
unansw
whether
treatment
lead
suppress
inflammatori
respons
infect
site
present
studi
hand
examin
effect
type
ifn
treatment
fulmin
ard
develop
mechan
unrel
viral
infect
may
aid
understand
therapeut
potenti
via
antiinflammatori
effect
separ
antivir
activ
although
remain
unclear
model
valid
analyz
pathogen
mechan
fulmin
ard
caus
influenza
viru
infect
clinic
import
condit
anim
model
bacteri
periton
acut
lung
injuri
associ
subarachnoid
hemorrhag
highdos
use
demonstr
antiinflammatori
effect
howev
present
studi
show
lowdos
effect
extend
surviv
time
fulmin
ard
mice
antiinflammatori
effect
lower
dose
recogn
current
studi
report
previou
investig
variou
anim
model
inflammatori
diseas
vitro
experi
amadori
et
al
shown
suppress
express
gene
swine
alveolar
macrophag
dosag
low
iuml
investig
also
report
oral
administ
suppress
express
inflammatori
cytokin
wean
piglet
contrast
cattl
parenter
administr
highdos
lowdos
actual
promot
inflammatori
respons
taken
togeth
previou
studi
present
find
suggest
lowdos
administr
may
exert
antiinflammatori
effect
inhibit
product
proinflammatori
cytokin
although
precis
mechan
remain
elucid
sever
mechan
propos
explain
antiinflammatori
effect
type
ifn
previou
studi
quin
et
al
interact
receptor
shown
trigger
induct
suppressor
cytokin
signal
regul
synthesi
inhibit
signal
transduc
activ
transcript
investig
also
report
antiinflammatori
effect
type
ifn
mediat
product
suppress
synthesi
gener
tristetraprolin
ttp
antiinflammatori
protein
studi
antiinflammatori
effect
associ
alter
synthesi
unlik
remark
reduct
synthesi
detect
lung
mice
group
data
shown
agreement
result
previous
report
critic
role
rather
role
limit
pathogenesi
fulmin
ard
develop
lpschalleng
mice
model
nkt
cell
monocyt
involv
synthesi
find
rais
possibl
may
amelior
effect
fulmin
ard
acceler
activ
lead
suppress
synthesi
nkt
cell
monocyt
howev
present
studi
attempt
address
precis
mechan
benefici
effect
remain
made
investig
need
clarifi
possibl
conclus
demonstr
lowdos
improv
surviv
fulmin
ard
mice
sensit
challeng
lp
suppress
product
subsequ
inflammatori
respons
result
suggest
cytokin
could
possibl
therapeut
option
ard
refractori
even
advanc
medic
therapi
current
avail
clinic
set
gener
higher
dose
type
ifn
administ
patient
hepat
viru
infect
multipl
sclerosi
howev
higher
dose
treatment
known
associ
variou
advers
effect
chill
fever
muscl
ach
headach
depress
respect
less
frequent
advers
effect
might
expect
addit
benefit
lower
dose
treatment
thu
present
studi
may
provid
signific
impetu
develop
promis
ard
treatment
